Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

Leukemia volume 23, pages 1679–1686 (2009)Cite this article

Abstract

Earlier studies have shown that ascorbic acid (vitamin C) inhibits bortezomib-induced cytotoxicity against cancer cells in vitro. However, the clinical significance of vitamin C on bortezomib treatment is unclear. In this study, we examined whether daily oral intake of vitamin C inhibits antimultiple myeloma (MM) activities of bortezomib. Vitamin C, at orally achievable concentrations, inhibited in vitro MM cell cytotoxicity of bortezomib and blocked its inhibitory effect on 20S proteasome activity. Specifically, plasma collected from healthy volunteers taking 1 g/day vitamin C reduced bortezomib-induced MM cell death in vitro. This antagonistic effect of vitamin C against proteasome inhibitors is limited to the boronate class of inhibitors (bortezomib and MG262). In vivo activity of this combination treatment was then evaluated using our xenograft model of human MM in SCID (severe combined immune-deficient) mice. Bortezomib (0.1 mg/kg twice a week for 4 weeks) significantly inhibits in vivo MM cell growth, which was blocked by oral vitamin C (40 mg/kg/day). Therefore, our results for the first time show that vitamin C can significantly reduce the activity of bortezomib treatment in vivo; and importantly, suggest that patients receiving treatment with bortezomib should avoid taking vitamin C dietary supplements.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB . Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 2008; 100: 773–783.

    Article  CAS  Google Scholar 

  2. Liu FT, Agrawal SG, Movasaghi Z, Wyatt PB, Rehman IU, Gribben JG et al. Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood 2008; 112: 3835–3846.

    Article  CAS  Google Scholar 

  3. Conklin KA . Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004; 3: 294–300.

    Article  CAS  Google Scholar 

  4. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS . Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 2005; 65: 8455–8460.

    Article  CAS  Google Scholar 

  5. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 2008; 19: 1969–1974.

    Article  CAS  Google Scholar 

  6. Pathak AK, Bhutani M, Guleria R, Bal S, Mohan A, Mohanti BK et al. Chemotherapy alone vs chemotherapy plus high dose multiple antioxidants in patients with advanced non-small cell lung cancer. J Am Coll Nutr 2005; 24: 16–21.

    Article  CAS  Google Scholar 

  7. Padayatty SJ . Vitamin C pharmacokinetics: implication for oral and intravenous use. Ann Int Med 2004; 140: 533–538.

    Article  CAS  Google Scholar 

  8. Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH et al. Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr 2003; 22: 18–35.

    Article  CAS  Google Scholar 

  9. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996; 93: 3704–3709.

    Article  CAS  Google Scholar 

  10. Head KA . Ascorbic acid in the prevention and treatment of cancer. Altern Med Rev 1998; 3: 174–186.

    CAS  PubMed  Google Scholar 

  11. Nagy B, Mucsi I, Molnar J, Varga A, Thurzo L . Chemosensitizing effect of vitamin C in combination with 5-fluorouracil in vitro. In Vivo 2003; 17: 289–292.

    CAS  PubMed  Google Scholar 

  12. Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW . Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 1996; 103: 183–189.

    Article  CAS  Google Scholar 

  13. Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008; 68: 8031–8038.

    Article  CAS  Google Scholar 

  14. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.

    Article  CAS  Google Scholar 

  15. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.

    Article  CAS  Google Scholar 

  16. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917.

    Article  CAS  Google Scholar 

  17. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007; 25: 3892–3901.

    Article  CAS  Google Scholar 

  18. Sonneveld P, Hajek R, Nagler A, Spencer A, Blade J, Robak T et al. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008; 112: 1529–1537.

    Article  CAS  Google Scholar 

  19. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006; 107: 1092–1100.

    Article  CAS  Google Scholar 

  20. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053–4062.

    Article  CAS  Google Scholar 

  21. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441–3449.

    Article  CAS  Google Scholar 

  22. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567–8572.

    Article  CAS  Google Scholar 

  23. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374–14379.

    Article  CAS  Google Scholar 

  24. Lin Z, Bazzaro M, Wang MC, Chan KC, Peng S, Roden RB . Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res 2009; 15: 570–577.

    Article  CAS  Google Scholar 

  25. Llobet D, Eritja N, Encinas M, Sorolla A, Yeramian A, Schoenenberger JA et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 2008; 19: 115–124.

    Article  CAS  Google Scholar 

  26. Fernandez Y, Miller TP, Denoyelle C, Esteban JA, Tang WH, Bengston AL et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem 2006; 281: 1107–1118.

    Article  CAS  Google Scholar 

  27. Zou W, Yue P, Lin N, He M, Zhou Z, Lonial S et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 2006; 12: 273–280.

    Article  CAS  Google Scholar 

  28. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257–264.

    Article  CAS  Google Scholar 

  29. Kim JE, Jin DH, Lee SD, Hong SW, Shin JS, Lee SK et al. Vitamin C inhibits p53-induced replicative senescence through suppression of ROS production and p38 MAPK activity. Int J Mol Med 2008; 22: 651–655.

    CAS  PubMed  Google Scholar 

  30. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943–2950.

    CAS  Google Scholar 

  31. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ . Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46: 673–683.

    CAS  PubMed  Google Scholar 

  32. Tsao CS, Leung PY, Young M . Effect of dietary ascorbic acid intake on tissue vitamin C in mice. J Nutr 1987; 117: 291–297.

    Article  CAS  Google Scholar 

  33. Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R . Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol 2008; 141: 494–503.

    Article  CAS  Google Scholar 

  34. Karasavvas N, Carcamo JM, Stratis G, Golde DW . Vitamin C protects HL60 and U266 cells from arsenic toxicity. Blood 2005; 105: 4004–4012.

    Article  CAS  Google Scholar 

  35. Schwedhelm E, Maas R, Troost R, Boger RH . Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet 2003; 42: 437–459.

    Article  CAS  Google Scholar 

  36. Henry EB, Carswell A, Wirz A, Fyffe V, McColl KE . Proton pump inhibitors reduce the bioavailability of dietary vitamin C. Aliment Pharmacol Ther 2005; 22: 539–545.

    Article  CAS  Google Scholar 

  37. Fujita I, Hirano J, Itoh N, Nakanishi T, Tanaka K . Dexamethasone induces sodium-dependant vitamin C transporter in a mouse osteoblastic cell line MC3T3-E1. Br J Nutr 2001; 86: 145–149.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA

    G Perrone, T Hideshima, H Ikeda, Y Okawa, E Calabrese, G Gorgun, L Santo, D Cirstea, N Raje, D Chauhan & K C Anderson

  2. Department of Hematology, Seràgnoli Institute of Hematology and Medical Oncology, Bologna University School of Medicine, Bologna, Italy

    G Perrone, M Baccarani & M Cavo

Authors
  1. G Perrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Hideshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Ikeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Okawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Calabrese
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Gorgun
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Santo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Cirstea
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. N Raje
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Chauhan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Baccarani
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Cavo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. K C Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K C Anderson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perrone, G., Hideshima, T., Ikeda, H. et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23, 1679–1686 (2009). https://doi.org/10.1038/leu.2009.83

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.83

Keywords

This article is cited by

Search

Advanced search

Quick links